Open Access
Subscription Access
Objectives, Symptoms, Mechanism of Action, Administration, Adverse Effects, Contraindications, Monitoring, Toxicity and Enhancing Health Care Team Outcomes of An Immuno Suppressive Drug Such as Cyclosporine
Abstract
An immunosuppressive medication called cyclosporine is useful in treating organ rejection following transplantation. Additionally, it shows promise in treating organ rejection in kidney, liver, and heart allogeneic transplants, rheumatoid arthritis, and other autoimmune illnesses where methotrexate has not been effective enough. Also, it is a second-line agent for ALS and graft vs host disease. Other FDA-approved and non-FDA-approved indications are also present. For interprofessional team members treating illnesses where cyclosporine is recommended, this activity explains the drug's mechanism of action, adverse event profile, toxicity, dosage, pharmacodynamics, and monitoring.
References
Pradier, A., Papaserafeim, M., Li, N., Rietveld, A., Kaestel, C., Gruaz, L., Vonarburg, C., Spirig, R., Puga Yung, G. L., & Seebach, J. D. (2019). Small-molecule immunosuppressive drugs and therapeutic immunoglobulins differentially inhibit NK cell effector functions in vitro. Frontiers in Immunology, 10, Article 556. https://doi.org/10.3389/fimmu.2019.00556
Canadian Agency for Drugs and Technologies in Health. (2018). Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.): Treatment of adult patients with active psoriatic arthritis who have responded inadequately to, or are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs). CADTH. https://www.ncbi.nlm.nih.gov/books/NBK542884/
Ponticelli, C., & Glassock, R. J. (2019). Prevention of complications from use of conventional immunosuppressants: A critical review. Journal of Nephrology, 32(6), 851–870. https://doi.org/10.1007/s40620-019-00621-8
Xin, G. L. L., Khee, Y. P., Ying, T. Y., Chellian, J., Gupta, G., Kunnath, A. P., Nammi, S., Collet, T., Hansbro, P. M., Dua, K., & Chellappan, D. K. (2019). Current status on immunological therapies for type 1 diabetes mellitus. Current Diabetes Reports, 19(5), Article 22. https://doi.org/10.1007/s11892-019-1134-0
Sun, S. L., Liu, J. J., Zhong, B., Wang, J. K., Jin, X., Xu, H., Yin, F. Y., Liu, T. N., Chen, Q. M., & Zeng, X. (2019). Topical calcineurin inhibitors in the treatment of oral lichen planus: A systematic review and meta-analysis. British Journal of Dermatology, 181(6), 1166–1176. https://doi.org/10.1111/bjd.18074
Liddicoat, A. M., & Lavelle, E. C. (2019). Modulation of innate immunity by cyclosporine A. Biochemical Pharmacology, 163, 472–480. https://doi.org/10.1016/j.bcp.2019.03.022
Masi, S., Uliana, M., Gesi, M., Taddei, S., & Virdis, A. (2019). Drug-induced hypertension: Know the problem to know how to deal with it. Vascular Pharmacology, 115, 84–88. https://doi.org/10.1016/j.vph.2019.02.002
Pal, P., Giri, P. P., & Sinha, R. (2019). Cyclosporine in resistant systemic arthritis: A cheaper alternative to biologics. Indian Journal of Pediatrics, 86(7), 590–594. https://doi.org/10.1007/s12098-019-02913-5
Shin, H. S., Grgic, I., & Chandraker, A. (2019). Novel targets of immunosuppression in transplantation. Clinics in Laboratory Medicine, 39(1), 157–169. https://doi.org/10.1016/j.cll.2018.10.010
Arslansoyu Camlar, S., Soylu, A., & Kavukçu, S. (2018). Cyclosporine in pediatric nephrology. Iranian Journal of Kidney Diseases, 12(6), 319–330.
Soleymani, T., Vassantachart, J. M., & Wu, J. J. (2016). Comparison of guidelines for the use of cyclosporine for psoriasis: A critical appraisal and comprehensive review. Journal of Drugs in Dermatology, 15(3), 293–301.
Patocka, J., Nepovimova, E., Kuca, K., & Wu, W. (2021). Cyclosporine A: Chemistry and toxicity—A review. Current Medicinal Chemistry, 28(20), 3925–3934. https://doi.org/10.2174/0929867327666200527092619
Refbacks
- There are currently no refbacks.